STW 5/Iberogast: Multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome;STW 5/Iberogast: Multi-target-wirkung bei funktioneller dyspepsie und reizdarmsyndrom

Wiener Medizinische Wochenschrift

Volumn 157, Issue 13-14, 2007, Pages 301-307

  Allescher, Hans Dieter ^a   Wagner, Hans Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Functional dyspepsia; Heartburn; Iberis amara; Irritable bowel syndrome; STW 5 Iberogast

Indexed keywords

CISAPRIDE; IBERIS AMARA; PLANT EXTRACT; STW 5; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; HEARTBURN; HUMAN; IBERIS AMARA; IRRITABLE COLON; MEDICINAL PLANT; MUCUS SECRETION; PLANT; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH ACID SECRETION; TREATMENT PLANNING;

ANIMALS; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; DYSPEPSIA; GUINEA PIGS; HUMANS; IRRITABLE BOWEL SYNDROME; META-ANALYSIS; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RATS;

EID: 34548381819     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0429-3     Document Type: Review

References (36)

1. Allescher HD (2006) Functional dyspepsia - A multicausal disease and its therapy. Phytomedicine 13: 2-11
2. Rösch W, Vinson B, Sassin I (2002) A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol 40: 401-408
3. Wagner H (2006) Multitarget therapy - The future of treatment for more than just functional dyspepsia. Phytomedicine 13: 122-129
4. Kroll U, Cordes C (2006) Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 13: 12-19
5. Simmen U, Kelber O, Okpanyi SN, Jäggi R, Bueter B, Weiser D (2006) Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 13: 51-55
6. Tack J (2004) Proximal gastric dysfunction in functional dyspepsia: Management options. Current Treatment Options Gastroenterol 7: 265-272
7. Hohenester B, Rühl A, Kelber O, Schemann M (2004) The herbal preparation STW5 (Iberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 16: 765-773
8. Schemann M, Michel K, Zeller F, Hohenester B, Rühl A (2006) Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. Phytomedicine 13: 90-99
9. Pilichiewicz AN, Horowitz M, Russo A et al. (2006) Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Neurogastroenterol Motil 18: 745
10. Pilichiewicz AN, Horowitz M, Russo A et al. (2007) Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol doi: 10.1111/j.1572-0241.2007. 01142.x
11. Ammon HPT, Kelber O, Okpanyi SN (2006) Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 13: 67-74
12. Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D (2006) Intestinal spasmolytic effects of STW 5 (Iberogast) and its components. Phytomedicine 13: 75-79
13. Yüce B, Wallbach J, Sibaev A, Schirra J, Kelber O, Göke B, Storr M (2006) Iberogast und seine Bestandteile bee-influssen den peristaltischen Reflex am Dünndarm der Ratte. Z Gastroenterol 44: 1091
14. Storr M, Sibaev A, Weiser D, Kelber O, Schirra J, Göke B, Allescher HD (2004) Herbal extracts modulate the amplitude and frequency of slow waves in circular smooth muscle of mouse small intestine. Digestion 70: 257-264
15. Liu C, Kreis M, Glatzle J et al. (2004) The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 16: 759-764
16. Michael S, Kelber O, Vinson B, Nieber K (2006) Herbal preparations STW 5 and STW 6 inhibit inflammation-mediated motility disorders in the ileum. UEGW Berlin A206
17. Abdel-Aziz H, Wadie W, Khayyal M T, Kelber O, Okpanyi S N, Weiser D (2007) Pharmacological evidence for the therapeutic spectrum of Iberogast in the upper and the lower gastrointestinal tract. Abstracts der Jahrestagung der Deutschen Gesellschaft für Neurogastroenterologie und Motilität, Hohenkammer, Deutschland, 23.-25. März 2007
18. Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S, Weiser D, Heinle H (2006) Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine 13: 45-50
19. Schempp H, Weiser D, Kelber O, Elstner EF (2006) Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine 13: 36-44
20. Beil W (1995) In vitro Untersuchungen mit Iberogast. Forschungsbericht, Institut für Allgemeine Pharmakologie der Medizinischen Hochschule Hannover
21. Khayyal M, El-Ghazaly M, Kenawy S, Self-El-Nasr M, Mahran L, Kafafi Y, Okpanyi SN (2001) Antulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim Forsch Drug Res 51: 545-553
22. Khayyal MT, Seif-el-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D (2006) Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine 13: 56-66
23. Reichling J, Landvatter U, and Saller R (2002) Antimikrobielles Potential der fixen Arzneimittelkombination Iberogast Tinktur (STW 5) und ihrer Einzelpflanzenextrakte sowie der Forschungspräparate STW 5-II und STW 5-III. Forschungsbericht, Universität Heidelberg
24. Saller R, Pfister-Hotz G, Iten F, Melzer J, Reichling J (2002) Iberogast: Eine moderne phytotherapeutische Arzneimittelkombination zur Behandlung funktioneller Erkrankungen des Magen-Darm-Trakts (Dyspepsie, Colon irritabile) - von der Pflanzenheilkunde zur Evidence Based Phytotherapy. Forsch Komplementärmed Klass Naturheilkd 1: 1-20
25. Rösch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G (2006) Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 13: 114-121
26. Gundermann K, Godehardt E, Ulbrich M (2003) Efficacy of a herbal preparation in patients with functional dyspepsia: A meta-analysis of double-blind, randomized, clinical trials. Adv Therapy 20: 43-49
27. Melzer J, Rösch W, Reichling J, Brignoli R, Saller R (2004) Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 20: 1279-1287
28. Schnitker J, Schöneberg G (2000) Metaanalyse zur Auswirkung von Iberogast auf säurebedingte funktionelle Beschwerden des Magen-Darm-Traktes im Rahmen doppelblinder placebokontrollierter klinischer Studien. Forschungsbericht IAS / STW0201-01
29. Nicolay K (1984) Funktionelle Gastroenteropathien im therapeutischen Blindvergleich von Metoclopramid mit dem Phytopharmakon Iberogast. Functional gastroenteropathies in therapeutic blind comparison of Metoclopramide with the Phytopharmaceutical Iberogast. Gastroenterol Hepatol 2: 1-12
30. Madisch A, Holtmann G, Plein K, Hotz J (2004) Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19: 271-279
31. Allescher HD, Knapp G, Hartung J (2002) Treatment of non-ulcer dyspepsia: Prokinetics are effective. Scand J Gastroenterol 37: 618-620
32. Allescher H D, Storr M (2002) Medikamentöse Therapie von gastrointestinalen Motilitätsstörungen. Internist 43: 1566-1577
33. Buchert D (1994) Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie. Z Phytotherapie 15: 24-27
34. Madisch A, Melderis H, Mayr G, Sassin I, Hotz J (2001) Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterol 39: 511-517
35. Arnim U v, Peitz U, Schumacher M et al. (2004) Efficacy and tolerability of the phytopharmacon STW5 compared to placebo for treatment of patients with functional dyspepsia: A randomized, double-blind multicenter study. Gut 53: A284
36. Holtmann G, Adam B, Vinson B (2004) Evidenz-basierte Medizin und Phytotherapie bei funktioneller Dyspepsie und Reizdarmsyndrom: Eine systematische Analyse der verfügbaren Evidenz zum Präparat Iberogast. Wien Med Wochenschr 154: 528-534